Fludarabine-refractory chronic lymphocytic leukemia (CLL) infers a very poor prognosis, with a median life expectancy of o1 year. 1 Although alemtuzumab, the only registered drug for the treatment of fludarabine-refractory CLL, is effective in this patient category, its use is hampered by an increased risk of major opportunistic infections. Also, effectivity is rather low in patients with bulky disease. 1 The only means by which enduring remissions in patients with refractory CLL can be achieved is reduced-intensity allogeneic hematopoietic stem cell transplantation (RIST). Response to induction treatment before RIST is found to be an important determinant of long-term outcome as patients with high disease burden, particularly bulky lymphadenopathy at the time of transplantation or poor response to last treatment, have the tendency to relapse more often, whereas patients with progressive disease uniformly fare badly. 2 At present, no optimal induction regimen, especially for patients with chemo-refractory disease, has been established.
In relapsed B-cell non-Hodgkin lymphoma the DHAPregimen (dexamethasone, cytarabine and cisplatin (CDDP)) has been used as an effective salvage treatment and also as induction therapy before (autologous) stem cell transplantation. Moreover, a recent study showed improved efficacy of the addition of the anti-CD20 monoclonal antibody rituximab to a DHAP-based induction regimen. 3 Although at present platinumbased therapies are not often used in CLL, these data provide an incentive to investigate its efficacy in relapsed and refractory CLL.
A 36-year old male patient (patient 1) was referred to our clinic with progressive CLL, Rai stadium III with adverse prognostic characteristics (CD38 positivity, unmutated IgV Hgenes), and bulky lymphadenopathy. As shown in Table 1 , he Letters to the Editor had been treated extensively over a period of 1.5 years without response. At time of referral the patient had fludarabine-refractory disease according to the NCI criteria and cytogenetic analysis showed deletion of 17p (FISH probe p53 (Abbott-Vysis, Abbott Park, IL, USA)) in 87% of the CLL cells. R-DHAP (dexamethasone 40 mg days 1-4, CDDP 100 mg/m 2 day 1, cytarabine 2 Â 2 g/m 2 day 2 and rituximab 375 mg/m 2 day 5, every 3 weeks) was chosen as induction regimen and a donor search for allogeneic stem cell transplantation was initiated. Already within a few weeks after the first cycle of therapy, the peripheral blood lymphocyte count decreased more than 20-fold from 78 Â 10 9 /l to 3.3 Â 10 9 /l. To further study the efficacy of this regimen, we next retrospectively analyzed nine additional CLL patients with chemorefractory disease treated with R-DHAP. Patient characteristics are presented in Table 1 . The mean age of the patients was 54 years. One patient had a WHO performance status (PS) of 2; otherwise the PS was 0-1 at the time of first cycle of R-DHAP. Seven patients had high-risk disease based on the Raiclassification and eight patients had bulky lymphadenopathy, defined as lymphadenopathy 45 cm. Cytogenetic abnormalities, including two cases of 17p deletion and two cases of 11q deletion, were found in four patients. All patients had undergone multiple preceding therapies as indicated. Nine patients had previously been treated with fludarabine; six of whom suffered from relapse within 6 months; and the remaining three within 1 year.
A total of 1-4 cycles of R-DHAP was administered. Eight of the ten patients responded (80%); a partial remission, as defined by the revised iwCLL-criteria, was obtained in seven out of ten patients and a complete response in one patient. In this patient the absence of minimal residual disease was confirmed by fourcolor flowcytometry. One of the two patients with del 17p and both patients with del 11q responded. It is interesting to note that a significant decrease in lymphadenopathy was attained in six out of eight patients with bulky disease. One patient developed tumor-lysis syndrome after the first cycle of R-DHAP, for which one dose of rasburicase was administered. All patients experienced grade III or IV hematological toxicity, although treatment effects could not always be discriminated from disease-related cytopenias. No life-threatening events occurred. Three patients developed infectious complications, requiring in-hospital antibiotic treatment (grade III). Six patients (nos. 3, 5-7, 9 and 10) subsequently underwent RIST; there was no appropriate donor available for patient 2 (Sib or MUD), whereas patients 1, 4 and 8 were considered not eligible for stem cell transplantation. Follow-up after the last cycle of R-DHAP is too short to draw firm conclusions, as the end-points of progressionfree survival and overall survival have not yet been reached in five patients. However, progression-free survival and overall survival extended beyond the median follow-up of 12 months in 3 and 5 patients, respectively.
Knowledge about mechanisms by which drug-resistance is overcome by this regimen and which constituents of the regimen are important in this process will provide valuable information for further research into treatment modalities for chemo-refractory CLL.
We studied in vitro sensitivity to fludarabine (F-ara-A) on serial blood samples taken from patient 1 before and 24 and 48 h after the treatment was started (before administration of cytarabine) and found that in vitro F-ara-A resistance was abolished following 48 h of in vivo treatment ( Figure 1a) . As both CDDP and dexamethasone are administered during the first 48 h of the R-DHAP regimen, we attempted to dissect the contribution of these drugs to the observed synergy with F-ara-A in both p53 functional (n ¼ 3) and dysfunctional (n ¼ 3) CLL samples. As expected, p53-functional CLL cells were sensitive to 10 mM F-ara-A, whereas p53-dysfunctional CLL samples were not. Co-treatment with 10 mM dexamethasone, but especially 10 mM CDDP, resulted in a synergistic response, importantly also in p53-dysfunctional samples (Figure 1b) . Although these in vitro data are preliminary, this observation needs to be investigated further, as it may offer insight into new possibilities to overcome p53-dysfunction in drug-responses in CLL.
In our retrospective analysis, we found marked activity of the R-DHAP regimen in chemo-refractory CLL, of note also in patients with bulky lymphadenopathy. Synergistic interactions between nucleoside analogs and oxaliplatin have been described in early stage, previously untreated CLL samples, 4 but our data suggest that also in patients with fludarabine resistance sensitivity to this drug can be enhanced by platinumbased compounds.
However, before the R-DHAP regimen can be generally considered as a treatment option in high-risk CLL patients, the results of a current prospective Dutch/Belgian HOVON trial studying the efficacy and tolerability of this regimen before allo-SCT in CLL patients with fludarabine-resistant disease, should be awaited. Our findings are in line with a previous small study, in which two courses of DHAP followed by alemtuzumab were Presented is the percentage of cell death upon F-ara-A treatment corrected for baseline apoptosis of the sample (mean þ s.e.m. of four tests; Mann-Whitney U test). (b) p53-dysfunctional (p53À; n ¼ 3) and p53-dysfunctional (p53 þ ; n ¼ 3) CLL samples were treated with 10 mM cisplatin (CDDP) or 10 mM dexamethasone (dexa) combined with 10 mM F-ara-A. To assess synergy, drug interactions were analyzed as described by Kaspers et al. 8 In short, actual survival (as assessed by MitoTracker staining) is plotted against expected survival, calculated from the survival rates of samples treated with the individual drugs. The diagonal line represents the situation in which actual survival ¼ predicted survival. Dots beneath this line indicate synergistic drug interactions (as actual survival ¼ opredicted survival).
used as conditioning regimen before autologous transplantation in chemo-refractory CLL. 5 In addition, a phase I-II trial in which a comparable regimen (OFAR; consisting of oxaliplatin, fludarabine, cytarabine and rituximab) was used, yielded moderate though encouraging results in chemo-refractory patients; 33% patients with fludarabine-resistant CLL (and 37% of patients with documented deletion of 17p) responded. 6 Together these results provide a rationale to explore the efficacy and mechanism of action of platinum-based regimens in this patient category. A drawback of regimens containing platinum-based compounds is the rather substantial risk of hematological toxicity, especially in patients with already compromised hematopoiesis because of the disease. Therefore, the potential benefit of alternative regimens like the combination of high-dose methylprednisolone and rituximab, which showed considerable activity (an overall response rate of 93%) in a small study in a similar patient group, and the newer targeted compounds (reviewed by Tsimberidou and Keating 7 ), should be explored unabatedly.
NUP98 is a promiscuous gene involved in chromosomal aberrations with more than 20 different partner genes in a variety of human hematological malignancies.
1,2 These rearrangements all lead to the expression of hybrid proteins that start with the amino-terminal moiety of NUP98. This amino-terminal domain contains multiple copies of a glycine-leucine-phenylalanine-glycine core motif, known to recruit the CBP/p300 acetyltransferases. 3 Evidence from overexpressions studies in mouse bone marrow (BM) progenitors indicates that the NUP98-fusion proteins induce leukemic transformation through the upregulation of Hoxa genes and the Hox cofactor Meis1. Expression of Hoxa, most frequently Hoxa7, Hoxa9 and Hoxa10 is postulated to induce a self-renewal stem cell-like program that likely contributes to the leukemic process. 4, 5 High mobility group (HMG) proteins are non-histone chromatin-associated proteins that bind to DNA with limited or no sequence specificity. Among them, HMGB proteins are important architectural facilitators of nucleosome remodelling and possibly of transcription factor's interaction with DNA (for a review, see Travers 6 ). The expression of the murine Hmgb3 gene is tightly regulated during hematopoiesis and is required in early steps of hematopoietic stem cell development in which it regulates cell-fate decisions. It is expressed in common myeloid and lymphoid progenitors (CMP and CLP) and except in the erythroid cells, it must be downregulated for the proper differentiation of both lineages to take place. 7, 8 Hmgb3 RNA has recently been found to be part of an embryonic stem cell-like transcription signature that was defined in mouse models of mixed-lineage leukemia (MLL)-mediated leukemic transformation and was also reported to be transiently upregulated during myeloid differentiation. 9 We earlier reported the involvement of NUP98 in t(X;11)(q28;p15) in a 73-year-old woman with therapy-related acute myeloblastic leukemia (AML) with M4 subtype. 1 Fluorescence in situ hybridization experiments performed on metaphasic chromosome of the blast cells permitted the mapping of the translocation breakpoint on Xq28 in which only the HMGB3 gene had the correct transcription orientation (telomere to
